Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets

Collaboration expands access to science-led, microbiome-friendly skincare solutions in Mexico and across new markets in EMEA, including launches in the Czech Republic, Slovakia, Ukraine, Bulgaria and Kazakhstan.

LAVAL, QC, Sept. 8, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering probiotherapeutical skincare products, announced the continued expansion of their strategic collaboration in Mexico and across additional EMEA markets following the 2025 launch in Poland.

The expansion includes both portfolio and geographic growth in recent months. In Poland, Bausch Health expanded its dermatology portfolio to include YUN's eczema-prone skincare solutions, building on last year's launch of YUN's probiotic-based skincare solutions for acne-prone skin. Geographic expansion has included launches of YUN's acne- and eczema-prone skincare solutions in the Czech Republic, Slovakia, Ukraine, Bulgaria, along with the introduction of YUN's skincare solutions in Mexico. The rollout is expected to continue in Kazakhstan in October 2026. This next phase of the collaboration reflects both companies' shared ambition to expand access to science-led, microbiome-friendly skincare solutions across EMEA and select international growth markets.

"Following our collaboration in Poland, YUN has entered and is continuing to enter additional markets as part of our broader EMEA growth strategy," said Cees Heiman, Senior Vice President, Europe & Canada, Bausch Health. "These launches reflect our commitment to bringing differentiated, science-based healthcare and skincare solutions to patients and consumers across the region. EMEA remains a strategically important geography for Bausch Health, and we see strong potential for YUN's microbiome-focused approach in markets such as Ukraine, Bulgaria, Czech Republic, Slovakia and Kazakhstan."

"Bringing YUN to Mexico expands our dermatology portfolio with skincare solutions grounded in microbiome science," said Fernando Zarate, Vice President, Latin America, Bausch Health. "This launch reflects our focus on identifying differentiated products that address evolving skincare needs and broaden access to innovative dermatology offerings in the Mexican market."

"We are proud to deepen our collaboration with Bausch Health and to see YUN entering additional international markets," said Tom Verlinden, CEO and Founder of YUN. "Our mission is to harness microbiome science through YUN Probiotherapy™, creating effective, natural and scientifically grounded solutions that respect the body's own balance. Expanding into Ukraine, Bulgaria, Czech Republic, Slovakia, Kazakhstan, and Mexico allows us to bring that mission to more people together with a partner that combines scale, credibility and strong regional execution."

YUN has developed YUN Probiotherapy™, a proprietary microbiome technology platform enabling the stable use of live probiotics in skincare formulations designed to support the skin's natural ecosystem. Through this expanded partnership, Bausch Health and YUN are strengthening the brand's presence across selected EMEA markets and Mexico while increasing access to innovative probiotherapeutical skincare solutions.

About YUN

YUN is a Belgian biotech company pioneering a new approach to everyday care through microbiome science. Founded in 2016, YUN developed the patented YUN Probiotherapy™ technology platform, combining live probiotics with pre- and postbiotics and microbiome-friendly formulations designed to respect and support the skin's natural microbiome. With innovations across dermatological, oral, baby, intimate, and ear care, YUN delivers science- and quality-driven, nature-powered solutions for patients and consumers, today and for generations to come. For more info about YUN, visit our site www.yun-probiotherapy.com or follow us on Linkedin.

About Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

Forward-looking Statements

This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Investor Contact:

Garen Sarafian 

[email protected]

(877) 281-6642 (toll free) 

Media Contact: 

Katie Savastano

[email protected]

(908) 569-3692

SOURCE Bausch Health Companies Inc.

Share this article

- Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases

- Strong clinical evidence demonstrates the device's high rates of safety and effectiveness in treating AFib patients

- FDA approval of TactiFlex Duo strengthens Abbott's expanding PFA portfolio following recent cardiac ablation approvals in the U.S., Europe, Asia and Latin America

ABBOTT PARK, Ill., Sept. 8, 2026 /PRNewswire/ -- Abbott, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients with challenging cases of atrial fibrillation (AFib). The U.S. approval of this dual-energy catheter, the latest generation of Abbott's cardiac ablation technology, marks a significant milestone in Abbott's commitment to advancing therapies that help physicians treat complex heart rhythms with greater precision and flexibility. Abbott will soon begin cases with broader commercial adoption across the country in the coming weeks.

Why cardiac ablation matters for people with AFib

For the 10.5 million people in the U.S. who live with a heart that beats too fast, too slow or in an irregular way, treatment is critical as AFib increases the risk of serious complications, including stroke.1,2 While many people are treated with medications, others require cardiac ablation, a minimally invasive procedure that targets the tissue responsible for abnormal electrical signals in the heart.

TactiFlex Duo is Abbott's latest ablation catheter designed to give physicians more flexibility when treating AFib. The technology allows physicians to use pulsed field ablation (PFA), radiofrequency (RF) energy, or a combination of both during a procedure, helping them tailor treatment to each patient's needs. Abbott's EnSite™ X EP System also provides physicians with real-time feedback as an integrated mapping solution with the PFA Index (PI), a tool designed to assess lesion formation during ablation with TactiFlex Duo. The dual-energy approach means physicians can create precise therapeutic lesions, or small areas of scar tissue, that block the abnormal electrical signals causing an irregular heartbeat while helping minimize the impact on surrounding healthy tissue. Successfully treating these areas can help restore the heart's normal rhythm and improve outcomes for patients living with AFib.

"Electrophysiology is rapidly evolving as physicians adopt new technologies that improve the safety and effectiveness of AFib treatment," said Atul Verma, M.D., Director of Cardiology at the McGill University Health Centre in Montreal, Canada, and a globally recognized expert in pulsed field ablation technology. "TactiFlex Duo provides physicians with greater flexibility during procedures, and when it is combined with the high-resolution 3D visualization available through Abbott's EnSite X mapping system, physicians have a suite of practice-changing tools to confidently treat patients with complex AFib."

Safety and effectiveness data support TactiFlex Duo FDA approval  

The FDA approval of TactiFlex Duo was secured based on the results from Abbott's FlexPulse IDE study. Late-breaking data from the study recently presented at the European Society of Cardiology (ESC) Congress 2026, which was simultaneously published in EP Europace, showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib (irregular heart rhythm episodes that come and go).

"TactiFlex Duo represents an important advancement as Abbott builds the industry's most comprehensive electrophysiology portfolio," said Uri Yaron, senior vice president of Abbott's electrophysiology business. "From diagnosis, mapping and intracardiac ultrasound imaging to advanced treatments for the most complex arrhythmias, Abbott is uniquely positioned to support physicians at every stage of patient care. By continuing to expand our PFA portfolio and integrate innovative technologies across cardiovascular care, we're helping physicians navigate increasingly complex procedures while ensuring more patients receive the right care at the right time."

Regulatory momentum across Abbott's PFA portfolio

The U.S. FDA approval of TactiFlex Duo further expands Abbott's portfolio of technologies designed to help physicians treat patients with cardiac arrhythmias. It is the company's fifth major electrophysiology approval in just over a year, following Europe's Amulet 360™ and TactiFlex Duo CE Mark approvals this year, and U.S. and European approvals of the Volt™ PFA System in 2025.

Frequently Asked Questions

What is TactiFlex Duo?

TactiFlex Duo is an advanced cardiac ablation catheter designed to treat irregular heart rhythms. Its dual-energy feature combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single device, allowing physicians to tailor treatment to each patient's unique needs during AFib ablation procedures.  

How do physicians know the precise locations in the heart to treat patients with TactiFlex Duo?  

TactiFlex Duo is integrated with Abbott's EnSite X EP System, a sophisticated mapping system that creates highly detailed three-dimensional maps of the heart to help doctors find and treat the source of an irregular heartbeat. Working together with Abbott's Advisor™ HD Grid X mapping catheter, ViewFlex™X ICE (intracardiac echocardiography) catheter and EnSite Echo Module, the integrated portfolio is designed to give physicians real-time images of the ablation catheter's positioning and movement, and a digital model of the patient's heart throughout a procedure. The EnSite X EP System also provides physicians with real-time information – called PFA index – which shows how the small areas of scar tissue created by TactiFlex Duo's pulsed field energy develop during an ablation procedure.3 

Who may need an ablation using TactiFlex Duo?

Patients with atrial fibrillation, particularly those with complex anatomy, prior or failed ablations or other challenging clinical situations, may benefit from treatment with TactiFlex Duo as determined by their physician. 

What are the patient benefits of being treated with TactiFlex Duo?

The catheter offers physicians greater procedural flexibility and precision through dual-energy capabilities, helping treat irregular heart rhythms while reducing the potential for damage to surrounding tissue. Clinical data has shown the technology to be safe and effective.

For U.S. important safety information go to:

TactiFlex Duo Ablation Catheter, Sensor Enabled

Advisor HD Grid X Mapping Catheter, Sensor Enabled™

ViewFlex X ICE Catheter, Sensor Enabled™ and EnSite Echo Module

The Amulet 360™ Left Atrial Appendage Occluder is approved for investigational use only in the U.S.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic 3 medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

SOURCE Abbott

Share this article

Bausch Health i YUN ogłaszają ekspansję na rynek meksykański oraz kolejne rynki regionu EMEA

Współpraca zwiększa dostęp do opartych na wiedzy naukowej, przyjaznych mikrobiomowi rozwiązań w zakresie pielęgnacji skóry w Meksyku oraz na nowych rynkach regionu EMEA, w tym poprzez wprowadzenie produktów na rynek w Czechach, na Słowacji, Ukrainie, w Bułgarii i Kazachstanie.

LAVAL (Quebec), 8 września 2026 r. /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), globalne, zdywersyfikowane przedsiębiorstwo farmaceutyczne, oraz YUN, belgijski innowator w dziedzinie pionierskich probiotykoterapeutycznych produktów do pielęgnacji skóry, ogłosiły dalsze rozszerzenie swojej strategicznej współpracy na Meksyk oraz kolejne rynki regionu EMEA po wprowadzeniu produktów na rynek polski w 2025 r.

W ostatnich miesiącach ekspansja objęła zarówno rozszerzenie portfolio, jak i zasięgu geograficznego. W Polsce Bausch Health rozszerzyło swoje portfolio dermatologiczne o rozwiązania YUN do pielęgnacji skóry z tendencją do egzemy, kontynuując rozwój zapoczątkowany ubiegłorocznym wprowadzeniem rozwiązań YUN do pielęgnacji skóry trądzikowej, opartych na probiotykach. Ekspansja geograficzna objęła wprowadzenie rozwiązań YUN do pielęgnacji skóry trądzikowej i skóry z tendencją do egzemy na rynki Czech, Słowacji, Ukrainy i Bułgarii, a także wprowadzenie rozwiązań YUN do pielęgnacji skóry na rynek meksykański. Oczekuje się, że ekspansja będzie kontynuowana w Kazachstanie w październiku 2026 r. Ten kolejny etap współpracy odzwierciedla wspólną ambicję obu przedsiębiorstw, aby zwiększać dostęp do opartych na wiedzy naukowej, przyjaznych mikrobiomowi rozwiązań w zakresie pielęgnacji skóry w regionie EMEA oraz na wybranych międzynarodowych rynkach wzrostu.

„Po nawiązaniu współpracy w Polsce YUN weszło na kolejne rynki i nadal rozszerza na nie swoją działalność w ramach naszej szerszej strategii wzrostu w regionie EMEA" - powiedział Cees Heiman, starszy wiceprezes ds. Europy i Kanady w Bausch Health. „Wprowadzenie tych produktów na kolejne rynki odzwierciedla nasze zaangażowanie w udostępnianie pacjentom i konsumentom w całym regionie wyróżniających się, opartych na wiedzy naukowej rozwiązań w zakresie ochrony zdrowia i pielęgnacji skóry. Region EMEA pozostaje obszarem o strategicznym znaczeniu dla Bausch Health i dostrzegamy duży potencjał podejścia YUN skoncentrowanego na mikrobiomie na takich rynkach jak Ukraina, Bułgaria, Czechy, Słowacja i Kazachstan".

„Wprowadzenie YUN na rynek meksykański rozszerza nasze portfolio dermatologiczne o rozwiązania do pielęgnacji skóry oparte na badaniach nad mikrobiomem" - powiedział Fernando Zarate, wiceprezes Bausch Health ds. Ameryki Łacińskiej. „Wprowadzenie tych produktów na rynek odzwierciedla nasze dążenie do oferowania wyróżniających się rozwiązań odpowiadających na zmieniające się potrzeby w zakresie pielęgnacji skóry oraz do zwiększania dostępu do innowacyjnych produktów dermatologicznych na rynku meksykańskim".

„Jesteśmy dumni z pogłębiania naszej współpracy z Bausch Health oraz z tego, że YUN wchodzi na kolejne rynki międzynarodowe" - powiedział Tom Verlinden, dyrektor generalny i założyciel YUN. „Naszą misją jest wykorzystywanie wiedzy o mikrobiomie poprzez YUN Probiotherapy™ do tworzenia skutecznych, naturalnych i opartych na podstawach naukowych rozwiązań, które respektują naturalną równowagę organizmu. Ekspansja na rynki Ukrainy, Bułgarii, Czech, Słowacji, Kazachstanu i Meksyku pozwala nam realizować tę misję z korzyścią dla większej liczby osób, wspólnie z partnerem łączącym szeroki zasięg, wiarygodność i silne możliwości działania na rynkach regionalnych".

YUN opracowało YUN Probiotherapy™, autorską platformę technologiczną opartą na mikrobiomie, umożliwiającą stabilne stosowanie żywych probiotyków w formulacjach produktów do pielęgnacji skóry, opracowanych w celu wspierania jej naturalnego ekosystemu. Dzięki rozszerzeniu współpracy Bausch Health i YUN wzmacniają obecność marki na wybranych rynkach regionu EMEA oraz w Meksyku, jednocześnie zwiększając dostęp do innowacyjnych probiotykoterapeutycznych rozwiązań w zakresie pielęgnacji skóry.

YUN

YUN to belgijskie przedsiębiorstwo biotechnologiczne, które wyznacza nowe kierunki w codziennej pielęgnacji dzięki wykorzystaniu wiedzy o mikrobiomie. Założone w 2016 r. przedsiębiorstwo YUN opracowało opatentowaną platformę technologiczną YUN Probiotherapy™, łączącą żywe probiotyki z prebiotykami i postbiotykami oraz formulacjami przyjaznymi mikrobiomowi, opracowanymi z myślą o poszanowaniu i wspieraniu naturalnego mikrobiomu skóry. Dzięki innowacjom w zakresie pielęgnacji dermatologicznej, jamy ustnej, niemowląt, okolic intymnych i uszu YUN oferuje pacjentom i konsumentom rozwiązania oparte na wiedzy naukowej i wysokiej jakości, wykorzystujące potencjał natury - dziś i z myślą o przyszłych pokoleniach. Więcej informacji o YUN można znaleźć na stronie www.yun-probiotherapy.com lub śledząc nas na Linkedin.

Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) to globalne, zdywersyfikowane przedsiębiorstwo farmaceutyczne, które poprawia jakość życia dzięki konsekwentnemu dążeniu do osiągania lepszych wyników opieki zdrowotnej. Opracowujemy, wytwarzamy i wprowadzamy do obrotu szeroką gamę produktów przede wszystkim w obszarach gastroenterologii, hepatologii, neurologii, dermatologii, stomatologii, medycyny estetycznej, produktów farmaceutycznych na rynkach międzynarodowych oraz ochrony zdrowia oczu, za pośrednictwem Bausch + Lomb Corporation, w której posiadamy pakiet kontrolny. Naszą ambicją jest być globalnie zintegrowanym przedsiębiorstwem z sektora ochrony zdrowia, cieszącym się zaufaniem i uznaniem pacjentów, pracowników ochrony zdrowia, pracowników oraz inwestorów. Więcej informacji o Bausch Health można znaleźć na stronie https://www.bauschhealth.com/ oraz na profilu przedsiębiorstwa w serwisie LinkedIn.

Wypowiedzi prognozujące

Niniejszy komunikat prasowy może zawierać wypowiedzi prognozujące w rozumieniu obowiązujących przepisów prawa dotyczącego papierów wartościowych, w tym przepisów „Safe Harbor" zawartych w amerykańskiej ustawie Private Securities Litigation Reform Act z 1995 r. Wypowiedzi prognozujące można zasadniczo rozpoznać po użyciu takich słów i wyrażeń jak „będzie", „przewiduje", „ma nadzieję", „oczekuje", „zamierza", „planuje", „powinien", „mógłby", „może", „uważa", „z zastrzeżeniem", a także ich odmian lub wyrażeń o podobnym znaczeniu. Wypowiedzi te nie stanowią ani faktów historycznych, ani zapewnień co do przyszłych wyników, lecz opierają się na aktualnych oczekiwaniach i przekonaniach kierownictwa oraz podlegają określonym ryzykom i niepewnościom, które mogą spowodować, że rzeczywiste wyniki będą istotnie różnić się od wyników opisanych w wypowiedziach prognozujących. Rzeczywiste wyniki podlegają również innym ryzykom i niepewnościom odnoszącym się szerzej do całokształtu działalności Bausch Health, w tym czynnikom opisanym bardziej szczegółowo w najnowszych raportach rocznych i kwartalnych Bausch Health oraz przedstawianym okresowo w innych dokumentach składanych przez Bausch Health do amerykańskiej Komisji Papierów Wartościowych i Giełd (U.S. Securities and Exchange Commission) oraz Kanadyjskich Administratorów Papierów Wartościowych (Canadian Securities Administrators), przy czym czynniki te zostają włączone do niniejszego dokumentu przez odniesienie. Czytelnikom zaleca się, aby nie polegali nadmiernie na żadnych z tych wypowiedzi prognozujących. Niniejsze wypowiedzi prognozujące odnoszą się wyłącznie do stanu na dzień sporządzenia niniejszego dokumentu. Przedsiębiorstwo nie zobowiązuje się do aktualizowania żadnych z tych wypowiedzi prognozujących w celu odzwierciedlenia zdarzeń, informacji lub okoliczności zaistniałych po dacie niniejszego komunikatu prasowego ani w celu odzwierciedlenia rzeczywistych wyników, chyba że obowiązek taki wynika z przepisów prawa.

Kontakt dla inwestorów:

Garen Sarafian

e-mail: [email protected]

tel. (877) 281-6642 (numer bezpłatny)

Kontakt dla mediów:

Katie Savastano

e-mail: [email protected]

tel. (908) 569-3692

Share this article

Limited-time Sweet Peach Tart flavor brings the iconic beauty brand's peachy aesthetic to the Yogurtland cup from September 7–27

FARMERS BRANCH, Texas, Sept. 8, 2026 /PRNewswire/ -- Yogurtland, the leading self-serve frozen yogurt brand, today announced its collaboration with Too Faced—the serious makeup brand who knows how to have fun--to celebrate the their new Peach Collection with an exclusive, limited-time frozen yogurt flavor: Sweet Peach Tart.

Available at participating Yogurtland locations nationwide now through Sept. 27, Sweet Peach Tart brings the essence of Too Faced's signature peach-inspired collection to the dessert counter. The vibrant frozen yogurt flavor swirls juicy peach sweetness with a refreshing, tangy finish and is topped with Too Faced Gummy Sweet Peach Rings for an extra burst of fruity flavor.

The collaboration brings together two brands known for turning everyday moments into playful experiences, pairing Too Faced's fearless, feminine approach to beauty with Yogurtland's customizable frozen yogurt experience.

"We're always looking for fun ways to surprise our guests and create flavors that feel timely, unexpected and incredibly craveable," said Sam Kwon, Head of Project Services & eCommerce at Yogurtland. "Partnering with Too Faced to bring its iconic Peach Collection to life in frozen yogurt form was a natural fit. Sweet Peach Tart is bright, playful and the perfect way to enjoy a little beauty-inspired sweetness."

"At Too Faced, we've always made makeup that looks good enough to eat, and now you finally can!," says Global Head of Beauty at Too Faced, Elyse Reneau. "Peach has such a special place in our hearts, and its sweet, juicy scent has always been part of what makes the collection so iconic. Partnering with Yogurtland lets us take that deliciousness one step further and bring the world of Too Faced Peach to life in a completely new way. Now you can wear your Peach and eat it too! It's fun, nostalgic, a little unexpected, and the sweetest way to celebrate the return of one of our most-loved collections."

The Too Faced Peach Collection offers a fresh take on the iconic collection, reimagined with modern formulas and shades while bringing back the irresistible scent fans remember. Now, fans can experience that same peach-inspired spirit in a completely new way at Yogurtland.

Sweet Peach Tart will be available at participating Yogurtland locations nationwide from September 7–27, while supplies last.

For more information, visit Yogurtland.com.

About Yogurtland:

Celebrating 20 years of delivering premium frozen yogurt experiences, Yogurtland is the industry-leading frozen yogurt chain that delivers over 200 handcrafted flavors and provides fans an anytime treat for the whole family. Made with real ingredients, Yogurtland creates froyo moments with expansive menu items and offerings, at-home experiences, and innovations throughout the brand. Yogurtland creates its one-of-a-kind roster of flavors through its Flavorologists, who are experts in flavor and masters of their craft. With scratch-made, handcrafted flavors from across the globe, fans can experience a truly customized frozen dessert. Yogurtland's premium frozen yogurt and delicious toppings are available through delivery, pickup, or catering, making it fun and easy to enjoy dessert anytime and anywhere. Presently, Yogurtland has more than 220 locations across the U.S. and internationally. For more information, visit www.yogurtland.com.

About Too Faced:

Too Faced is a serious makeup brand that knows how to have fun. We believe makeup is power, giving people the freedom to express themselves and the confidence to take over the world. With an exuberant approach to everything we do, we use the finest cutting-edge ingredients to create innovative, cruelty-free cosmetics that people love to wear. Create your own looks, find what you love and OWN YOUR PRETTY. Find us on TikTok @toofaced and Instagram @toofaced

SOURCE Yogurtland

Share this article

Ceremony Highlights One of America's Leading Utility Growth Businesses

SAN DIEGO, Sept. 8, 2026 /PRNewswire/ -- Sempra (NYSE: SRE) celebrated its next chapter of growth as Chairman and Chief Executive Officer Jeffrey W. Martin and members of the board of directors rang the opening bell at the New York Stock Exchange (NYSE). The ceremony reflected Sempra's continued momentum as it advances its mission to build America's leading utility growth business.

"We are pleased to celebrate our longstanding relationship with the NYSE as we renew our commitment to help lead our industry in meeting rising energy demand across some of America's largest and fastest-growing markets," said Jeffrey W. Martin, chairman and CEO of Sempra. "This is an exciting time for our company. By simplifying our business model and strengthening our financial position, we are better positioned to invest in critical energy infrastructure that serves nearly 40 million consumers. By continuing to enhance safety, reliability and resilience, we are working hard every day to create meaningful long-term value for our stakeholders."

To help meet growing energy demand, Sempra has refined its corporate strategy to strengthen its position in major economic markets and shift capital to meet the growing needs of its U.S. utilities.

"Across the next decade, we expect economic growth will be fueled by domestic manufacturing, investments in critical infrastructure and advances in AI technologies that reshape how America competes on the global stage. At Sempra, we understand that modernizing and expanding the energy grid is central to that effort," said Martin.

Sempra's utility growth strategy is supported by a record $65 billion capital plan,1 with approximately 95% of planned investments directed toward regulated utilities, alongside a capital recycling program designed to efficiently fund growth and strengthen the company's financial position. These actions reflect Sempra's disciplined execution of its 2026 value creation initiatives and support its objective of generating approximately 95% of earnings from regulated U.S. utilities in 2027, as well as having more than 60% of its rate base located in Texas through the end of the decade.2 The strategy is designed to support continued investment in modernizing and expanding energy infrastructure while helping power America's growing economy.

About Sempra

Sempra's mission is to build America's leading utility growth business. As owner of one of the largest energy networks on the continent, Sempra is electrifying and improving energy resilience in California and Texas, the two largest economies in the U.S. The company is recognized as a leader in responsible business practices and for its high-performance culture focused on safety and operational excellence, as demonstrated by Sempra's inclusion in The Wall Street Journal's Management Top 250 and Fortune's World's Most Admired Companies. More information about Sempra is available at sempra.com, including investor.sempra.com/corporate-updates which contains important information for investors, and on social media @sempra.

We use the investor.sempra.com/corporate-updates webpage as a means of disclosing important information to investors, some of which may be material, and complying with our disclosure obligations under SEC Regulation FD. The information on this webpage is supplemental to the information we disseminate to investors through other channels, including filings with the SEC, press releases, and public conference calls and webcasts, and investors should monitor all these sources for material information about us.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on assumptions about the future, involve risks and uncertainties, and are not guarantees. Future results may differ materially from those expressed or implied in any forward-looking statement. These forward-looking statements represent our estimates and assumptions only as of the date of this press release. We assume no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise.

In this press release, forward-looking statements can be identified by words such as "believe," "expect," "intend," "anticipate," "contemplate," "plan," "estimate," "project," "forecast," "envision," "should," "could," "would," "will," "confident," "may," "can," "potential," "possible," "proposed," "in process," "construct," "develop," "opportunity," "preliminary," "pro forma," "strategic," "initiative," "target," "outlook," "optimistic," "poised," "positioned," "maintain," "continue," "progress," "advance," "goal," "aim," "commit," or similar expressions, or when we discuss our guidance, priorities, strategies, goals, vision, mission, projections, intentions or expectations.

Factors, among others, that could cause actual results and events to differ materially from those expressed or implied in any forward-looking statement include: California wildfires, including potential liability for damages regardless of fault and any inability to recover all or a substantial portion of costs from insurance, the wildfire fund established by California Assembly Bill 1054 and the wildfire fund continuation account established by California Senate Bill 254, rates from customers or a combination thereof; decisions, disallowances or denials of cost recovery, audits, investigations, inquiries, ordered studies, regulations, legislative actions, denials or revocations of permits, consents, approvals or other authorizations, renewals of franchises, and other actions, including the failure to honor contracts and commitments, by the (i) Comisión Nacional de Energía, California Public Utilities Commission (CPUC), U.S. Department of Energy, Electric Reliability Council of Texas, Inc., U.S. Federal Energy Regulatory Commission, U.S. Internal Revenue Service, Public Utility Commission of Texas and other regulatory bodies and (ii) U.S., Mexico and states, counties, cities and other jurisdictions therein and in other countries where we do business; the success of business development efforts, construction projects, acquisitions, divestitures, and other significant transactions, such as the planned sale of a portion of our equity interest in Sempra Infrastructure Partners, including risks related to, as applicable, (i) being able to reach a positive final investment decision, (ii) negotiating pricing and other terms in definitive contracts, (iii) completing construction projects or other transactions on schedule and budget, (iv) realizing anticipated benefits from any of these efforts if completed, (v) obtaining regulatory and other approvals and (vi) third parties honoring their contracts and commitments, including with respect to closing or post-closing payments; changes to our capital expenditure plans and their potential impact on rate base or other growth; changes, due to evolving economic, political and other factors and increasing geopolitical instability as a result of wars or other conflicts in various parts of the world, to (i) trade and other foreign policy, including the imposition of tariffs by the U.S. and foreign countries (and uncertainty related to the implementation and enforceability thereof), and (ii) laws and regulations, including those related to tax and the energy industry in the U.S. and Mexico; litigation, arbitration, property disputes and other proceedings; cybersecurity threats, including by nation-state actors, of ransomware or other attacks on our systems, the energy grid or our other infrastructure, or the systems of third parties with which we conduct business; the availability, uses, sufficiency, and cost of capital resources and our ability to borrow money or otherwise raise capital on favorable terms and meet our obligations, which can be affected by, among other things, (i) actions by credit rating agencies to downgrade our credit ratings or place those ratings on negative outlook, (ii) instability in the capital markets, and (iii) fluctuating interest rates and inflation; the impact of efforts to increase affordability of U.S.

CDF Corporation Launches the Squiz® System in North America, Bringing Automated Liner Evacuation to Manufacturers of Thick, High-Value Liquids

New automated system recovers high-value product left behind in IBC liners, reducing product waste by up to 96 percent in manufacturer trials

PLYMOUTH, Mass., Sept. 8, 2026 /PRNewswire/ -- CDF Corporation, a manufacturer of flexible liners for industrial containers, today announced the North American launch of the Squiz® System, an automated liner evacuation system for intermediate bulk containers (IBCs). The system addresses a recurring and largely unmeasured source of product loss in liquid manufacturing: residual product retained inside the liner when an IBC is emptied.

For manufacturers of thick, slow-moving products that cling to the liner rather than dispensing completely, conventional pumping leaves product behind in every container. Across multiple container cycles per year, this residual product represents a measurable and recurring financial loss. With the Squiz System, an average of 0.1 to 0.2 percent of product remains after dispense. In manufacturer trials on thick cosmetic creams, product waste per liner fell by up to 96 percent.

At the core of the Squiz System is a controlled winding action: the machine winds the liner from the top down during dispense, in sync with the plant's pump, moving product toward the dispense valve. A reinforced form-fit liner withstands the mechanical load of winding.

"We are very pleased to be offering this unique solution that maximizes the emptying of viscous products. It not only saves the company money but it plays a big role in the overall goal of reducing waste that we all, as environmental custodians, are striving for," said Joe Sullivan, President and CEO of CDF Corporation.

How it works

Winds the IBC liner from the top down during dispense, in sync with a pump and a standard plant compressed-air connection on a dedicated line.

No operator intervention during dispense; automatic pressure cutoffs and an emergency stop are engineered in.

Mobile design: mounted on a stainless-steel frame with locking casters, the unit moves between production lines with no fixed installation and no electrical connection.

Developed in Europe, exclusive to CDF in North America

The Squiz System was developed by Liquidpack S.L. of Onda, Spain, where the system has been deployed across European manufacturing operations. CDF brings the system to the North American market together with its engineered form-fit liner, backed by CDF's Plymouth, Massachusetts manufacturing and support operations.

Live demonstrations at PACK EXPO International

CDF will run live Squiz System demonstrations at PACK EXPO International, October 18 to 21 at McCormick Place, Chicago, booth LU-6806 in the Reusable Packaging Pavilion. The Squiz System will be set up in the booth to demonstrate how the mechanism moves contents toward the dispense valve. Attendees can also estimate the cost of residual product loss in their own operations using CDF's Cost of Dispensing Calculator.

Manufacturers seeking to quantify residual product loss in their operations can request a technical review and on-site evaluation here.

About CDF Corporation

CDF Corporation is a Plymouth, Massachusetts based manufacturer of flexible liners for pails, drums, intermediate bulk containers, and bag-in-box packaging. For more than 50 years, CDF has helped manufacturers protect their containers, recover their product, and contain their risk across food and beverage, chemical, cosmetic, and industrial markets. CDF is an SQF-certified manufacturer with FDA-approved film options. Learn more at cdf1.com.

Media contact: Kate Connors, Marketing Manager, CDF Corporation | [email protected]

SOURCE CDF Corporation

Share this article

Teletrac Navman Appoints Ricardo Buranello as CEO

Alain Samaha to Continue Serving on Board of Directors

NORTHBROOK, Ill., Sept. 8, 2026 /PRNewswire/ -- Teletrac Navman, a leading global provider of intelligent fleet and asset management solutions, today announced that it has named current Chief Financial and Operating Officer Ricardo Buranello as Teletrac Navman's next Chief Executive Officer, effective October 1, 2026. Mr. Buranello succeeds Alain Samaha, who will continue in the CEO role through September 30, 2026, to ensure a seamless transition. Mr. Samaha will remain a member of Teletrac Navman's Board of Directors and continue supporting the Company's long-term vision and strategic planning.

Mr. Buranello is a seasoned executive with more than two decades of international experience across telematics, IoT, and high-growth technology businesses. Having served as Chief Financial and Operating Officer since joining Teletrac Navman, he brings deep financial and operational expertise, a strong strategic orientation, and an intimate knowledge of the business that make him ideally suited to lead the Company into its next chapter. Mr. Buranello previously held leadership roles at Telit Cinterion, Siemens and Totvs.

"This represents an ideal time for Teletrac's next phase of leadership, and we're confident that Ricardo is the right person for the job," said Jonathan Olefson, Chairman of the Board at Teletrac Navman. "Ricardo is a proven, mission-oriented leader who understands our business from the inside out. We look forward to what he and the entire team will accomplish."

"Alain helped transform Teletrac into a global leader in telematics and fleet management solutions. We are grateful for his vision, passion, and many contributions, and look forward to working with him on the Board," continued Olefson.

Mr. Samaha stated, "Leading Teletrac has been one of the great privileges of my professional life. I am proud of what we have done together, and I am equally excited about what lies ahead for Teletrac. Ricardo is the right leader for this moment. His strategic clarity and deep understanding of our business will serve Teletrac, our customers, and our employees well into the future."

Mr. Buranello added, "I am honored by the trust the Board has placed in me and energized by the opportunities ahead. Our customers, employees, and partners can count on the same dedication to innovation, excellence, and delivering meaningful results that has been at the core of Teletrac since the beginning."

Under Mr. Buranello's leadership, Teletrac Navman will continue advancing its cloud-based, AI-powered connected mobility platform while building on the growth, stability, and customer focus that have long defined the Company.

About Teletrac Navman

Teletrac Navman empowers the industries that transform and sustain our futures with simple and intelligent solutions that enhance the efficiency, safety, and sustainability of their operation. As a connected mobility platform for industries that manage vehicle and equipment assets, Teletrac Navman simplifies the complex so that its customers can transform the way they work through cloud-based solutions that leverage AI to unlock the power of operational insight. The company operates globally, with offices worldwide and headquarters in Northbrook, IL. For more information visit www.teletracnavman.com.

About Respida

Respida is a software-focused private equity firm with decades of combined investing and operating experience. The firm partners with management teams at growth-oriented software and software-enabled companies, bringing hands-on operational rigor and financial discipline to drive growth and build durable market leaders. For more information, visit respida.com.

Media Contact

SOURCE Teletrac Navman

Share this article

Axcelis to Build New Manufacturing Facility in Pyeongtaek, Korea

BEVERLY, Mass., Sept. 8, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, today announced plans to invest $35 million in its global manufacturing infrastructure through the construction of a new ion implantation equipment manufacturing facility in Pyeongtaek, Gyeonggi Province, Korea.

President and CEO Russell Low commented, "This investment reflects Axcelis' continued commitment to strengthening our global high volume manufacturing infrastructure and expanding the capabilities needed to serve our customers around the world. Ion implanters are among the most important tools in front-end semiconductor manufacturing. Building on our established presence in Korea, the new Pyeongtaek facility will enhance our ability to support growing global demand for semiconductors."

The Pyeongtaek site will encompass approximately 200,000 square feet of total gross floor area. The manufacturing center's design will provide a lean production environment that encompasses nearly 50 years of semiconductor capital equipment experience. The Pyeongtaek facility will integrate warehousing, Class 1,000 and Class 10,000 cleanrooms, and a training center, to enable fast and flexible responses to our customers' needs.

As part of this global manufacturing expansion, Robert Mahoney, Executive Vice President, Global Operations, participated in an Investment Declaration Ceremony in Washington, D.C., with representatives from the Ministry of Trade, Industry and Resources (MOTIR) and the Korea Trade-Investment Promotion Agency (KOTRA) last week. A groundbreaking ceremony will follow on October 20, 2026. Production at the new manufacturing facility is scheduled to commence in the second half of 2028.

About Axcelis

Axcelis (Nasdaq: ACLS), headquartered in Beverly, Mass., has been providing innovative, high-productivity solutions for the semiconductor industry for nearly 50 years. Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation systems, one of the most critical and enabling steps in the IC manufacturing process. Learn more about Axcelis at www.axcelis.com.

Safe Harbor Statement:

Statements made in this press release that are not of known historical fact are forward-looking statements and are subject to the safe harbor provisions created by the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and should be viewed with caution. They are subject to various risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, including the risks and uncertainties that are described in the documents filed or furnished by us with the Securities and Exchange Commission ("SEC"), including specifically the risk factors described in our most recent Annual Report on Form 10-K and other subsequent filings with the SEC. The Company undertakes no obligation to update the information or statements made in this press release.

CONTACTS:

Investor Relations Contact:

David Ryzhik

Senior Vice President and Interim CFO

Telephone: (978) 787-2352

Email: [email protected]

Press/Media Relations Contacts: 

Maureen Hart

Senior Director, Corporate & Marketing Communications

Telephone: (978) 787-4266

Email: [email protected]

SOURCE Axcelis Technologies, Inc.

Share this article

MIAMI, Sept. 8, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer and manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica® and Eddie Bauer® brands, today announced a new distribution partnership with Directed Electronics for Australia and New Zealand.

Under the agreement, Directed will serve as the exclusive distributor of Lucyd and Reebok smart eyewear products across Australia and New Zealand, supporting the development and expansion of the category across the region.

Directed brings more than 20 years of experience developing and bringing consumer electronics products and international brands to market across Australia and New Zealand. The partnership will combine Innovative Eyewear's growing smart eyewear portfolio with Directed's local retail relationships, distribution infrastructure, marketing capabilities, customer support and market-development expertise.

The companies intend to build the category through a staged go-to-market strategy spanning consumer electronics retail, digital channels and other relevant specialist channels as the portfolio develops. Initial launch planning is already underway across Australia and New Zealand, together with product certification, retail execution and local market-readiness activities.

Harrison Gross, CEO and Co-Founder of Innovative Eyewear, commented: "Australia and New Zealand represent exciting markets for the continued international expansion of our smart eyewear portfolio, and we are delighted to partner with Directed.

Directed brings strong local retail relationships, operational capability and a clear understanding of how to build emerging consumer technology categories. We believe their market-development approach is well aligned with our objective of making smart eyewear more accessible to consumers across a broad range of everyday, sporting and professional use cases.

We look forward to working closely with the Directed team to establish Lucyd and Reebok smart eyewear across the region."

Steve Siolis, CEO at Directed Electronics, said:

"We see smart eyewear developing into an important new consumer technology category, and our partnership with Innovative Eyewear gives us an opportunity to build that category properly across Australia and New Zealand.

Lucyd is the combination of practical everyday utility, open-ear audio, AI-enabled functionality, prescription capability and a portfolio that can ultimately address multiple customer and retail segments.

We are already progressing launch planning with retail partners across Australia and New Zealand and look forward to bringing the first ranges to market."

Lucyd Aero™

The Lucyd Aero™ collection represents the next generation of Innovative Eyewear's smart eyewear portfolio, combining open-ear audio and connected functionality within a lightweight eyewear form factor.

Innovative Eyewear currently expects the Aero collection to launch during Q4 2026.

About Innovative Eyewear, Inc.

Innovative Eyewear is a developer and manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica® and Eddie Bauer® brands.

True to its mission to Upgrade Your Eyewear®, the Company's Bluetooth-enabled audio eyewear allows users to remain connected to their digital lives through a wearable, open-ear form factor. Its portfolio includes a broad range of frame and lens combinations designed to address optical, sunglass, sporting and safety eyewear applications.

To learn more about Innovative Eyewear and its continuously evolving smart eyewear portfolio, please visit www.lucyd.co.

About Directed Electronics

Directed Electronics has more than 20 years of experience in the development, commercialisation and distribution of products and solutions across the automotive, mobile electronics and consumer electronics sectors in Australia and New Zealand.

Operating across OEM, Telematics and Retail divisions, Directed works with global technology and consumer brands to bring products to market through leading national retailers, specialist chains, independent stores, trade partners and OEM customers.

Directed's Australian head office and primary distribution centre are located at Melbourne Airport, Victoria, with representation across Australia and additional operations and warehousing in New Zealand.

To learn more about Directed, please visit www.directed.com.au.

Forward-Looking Statements

This press release contains certain forward-looking statements, including statements relating to distribution arrangements, product launches, retail expansion, market-development activities and future commercial opportunities.

Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions including, but not limited to, "anticipate," "believe," "continue," "estimate," "expect," "future," "intend," "may," "outlook," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although the absence of these words does not mean that a statement is not forward-looking.

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Important factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K under the caption "Risk Factors."

Investor Relations Contact

Skyline Corporate Communications Group, LLC

Scott Powell, President

1177 Avenue of the Americas, 5th Floor

New York, NY 10036

Office: +1 (646) 893-5835

Email: [email protected]

SOURCE Innovative Eyewear, Inc.

Share this article

Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League

- Hyundai Motor Company becomes Official Automotive Partner of the UEFA Champions League in a multi-year partnership, beginning with the 2026/27 season

- The competition sets the benchmark for European club football by bringing together the best in the game, a standard Hyundai measures itself against in its own field

- Designed in Europe for European customers, IONIQ 3 is the first of five major models Hyundai will launch in Europe during the 2026/27 season and the first to represent the brand in the partnership

OFFENBACH, Germany, Sept. 8, 2026 /PRNewswire/ -- Hyundai Motor Company today announced a multi-year agreement as the Official Automotive Partner of the UEFA Champions League. The partnership marks the company's commitment to European club football at its highest level. It begins with the 2026/27 season, running to the end of the 2030/31 season.

Football is familiar ground. For almost 30 years Hyundai has supported the game at its highest levels, from the largest international tournaments to clubs and associations around the world. The UEFA Champions League extends that commitment to the pinnacle of European club football.

The parallels between the UEFA Champions League and Hyundai run deeper than scale: squads in this competition draw talent from every corner of the globe and compete at the highest level in Europe. Hyundai leverages the strengths of its global scale while designing, engineering and building vehicles in Europe, selling across the continent. Two organisations, unambiguously European in operation and international in influence.

"Football has been part of Hyundai for almost 30 years. It brings people together like almost nothing else, across languages and borders and generations," said José Muñoz, President and Chief Executive Officer, Hyundai Motor Company. "The UEFA Champions League is the best club football in the world, played every week in front of the most passionate fans in Europe. Following Hyundai's engagement at the World Cup this summer, the UEFA Champions League is an ideal platform to show our beautifully designed vehicles with features fans love. I am from Madrid, so I have watched this competition my whole life. I'm personally excited about engaging with fans across Europe. It's a great time to celebrate the beautiful game with Hyundai."

Under its brand vision of 'Progress for Humanity', Hyundai is committed to expanding opportunities and contributing towards a more inclusive future for society. Through this partnership with UC3, UEFA's joint venture with European Football Clubs, engagement with the UEFA Champions League and Hyundai's mobility offerings, the company aims to bring people together across cultures and communities throughout Europe, uniting millions of football fans while delivering a positive impact for society.

"The UEFA Champions League and Hyundai are both driven by progress, performance, and the ambition to bring people together," said Xavier Martinet, President and Chief Executive Officer of Hyundai Motor Europe. "We are entering this partnership with our strongest line-up yet. IONIQ 3 is the first of five new models we are launching in Europe this season, designed and developed for our customers here in the region, and it is the car that leads our lineup for the future."

The UEFA Champions League is the world's most-watched annual club football competition with around one in three people being interested in the Champions League worldwide. The 36-club tournament provides a perfect platform to engage with a huge audience of passionate football fans and highlight Hyundai's future direction, from robotics and physical AI, to software and smart mobility solutions tailored for European customers.

Hyundai is a global brand with a strong footprint in Europe, built over more than 30 years. Its European Technical Centre in Rüsselsheim, Germany, develops and engineers its vehicles, while its European Design Centre at the same site shapes their visual look and identity. Production takes place at plants in the Czech Republic and Türkiye, with Hyundai vehicles reaching customers across 42 European markets through more than 2,000 sales and aftersales outlets. Hyundai's design, engineering, manufacturing and partner network supports customers and fans every day.

The IONIQ 3: Hyundai's entry on the pitch

The all-electric IONIQ 3, designed in Europe for European customers, is Hyundai's opening statement in the partnership. The compact hatchback made its debut at Milan Design Week earlier this year and became the first battery-electric vehicle to enter production at Hyundai's İzmit plant when manufacturing commenced in August. It is the first of five major new models Hyundai brings to Europe in the 2026/27 season.

With the IONIQ 3, Hyundai enters the compact class, Europe's most contested segment, with class-leading capability to deliver on European customers' needs. IONIQ 3's Aero Hatch typology has been created to deliver class-leading efficiency and range, with a drag coefficient of 0.263 Cd and up to 497 km of range (WLTP). With 441 liters of trunk volume, best-in-class interior space, a segment-leading 14.6-inch display featuring Hyundai's latest PLEOS Connect infotainment system, and strong value, IONIQ 3 represents Hyundai's commitment to making electrified mobility accessible to its European customers.

The IONIQ 3 sits within a line-up that offers customers a genuine choice across the full powertrain spectrum, thanks to Hyundai's flexible strategy: battery-electric, hybrid, plug-in hybrid, hydrogen fuel-cell electric and internal combustion. The range is structured around how people own and use their vehicles, delivering flexibility.

IONIQ 3 builds on Hyundai's EV recognition in Europe, following significant awards that reflect the breadth of the company's commitment to electrified mobility. The Hyundai INSTER was named 2025 World Electric Vehicle, while the IONIQ 9 was named Germany's 2026 Premium Car of the Year. This customer-centric focus frames Hyundai's newly announced partnership as the UEFA Champions League's Official Automotive Partner.

Guy-Laurent Epstein, Co-Managing Director, UC3: "We are delighted to welcome Hyundai as an official partner of the UEFA Champions League. Hyundai has a proud history of supporting football at the highest level and a clear belief in its power to bring people together. We look forward to building a partnership that brings that shared ambition to life for fans around the world over the coming years."

More information about Hyundai Motor and its products can be found at:

https://www.hyundai.com/worldwide/en/ or Newsroom: Media Hub by Hyundai

Follow our Hyundai Global Newsroom Instagram channel @hyundai_mediahub

More information about Hyundai Motor Europe HQ and its products is available at www.hyundai.news.

Follow Hyundai Motor Europe HQ on X @HyundaiEurope, Instagram @Hyundai.Europe and TikTok @Hyundai.Europe

SOURCE Hyundai Motor Company

Share this article